Tirzepatide is a dual-agonist peptide that simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Approved under the brand names Mounjaro® (diabetes) and Zepbound® (weight management), it demonstrated greater average weight reduction in clinical trials than single GLP-1 agonists like semaglutide. Compounded tirzepatide is available through licensed telehealth providers.
GLP-1 vs tirzepatide
While semaglutide targets only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP receptors simultaneously. Clinical trial data showed tirzepatide achieving up to 22.5% average body weight reduction at the highest dose in the SURMOUNT-1 trial — significantly greater than semaglutide's results in comparable studies. The dual mechanism also produces distinct metabolic effects on lipid metabolism due to the GIP component.
Availability through telehealth
Compounded tirzepatide is available through several online telehealth platforms including Hims, Ro, Eden, and Nexaph (as a raw research compound). Access requires clinician evaluation and a valid prescription. Pricing for compounded tirzepatide is typically higher than semaglutide due to the more complex synthesis process.
Regulatory status
Like semaglutide, compounded tirzepatide is not FDA-approved as a finished drug product. It is compounded by licensed pharmacies under federal guidelines. Eli Lilly's branded versions (Mounjaro®, Zepbound®) are FDA-approved. Patients should discuss the distinction between compounded and brand-name versions with their prescriber.
See all Tirzepatide vendors ranked
PeptideComparison independently scores every vendor on COA quality (weighted 2×), price, reviews, shipping, and availability. Click below to see the full ranked list filtered to Tirzepatide vendors.
View Tirzepatide vendor rankings →